Veeva Systems Inc. — Q3 FY2024 Form 10-Q
Reporting period: Quarter and nine months ended October 31, 2023; comparisons are with the corresponding 2022 periods. Veeva provides cloud software, data, analytics, professional services, and consulting, primarily to life sciences companies. Amounts below are rounded to millions unless noted.
Financial performance
| Metric | Q3 FY2024 | Year-over-year change | Nine months FY2024 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $616.5 | +12% | $1,733.1 | +9% |
| Subscription revenue | $494.9 | +12% | $1,380.1 | +8% |
| Professional services and other | $121.6 | +10% | $353.0 | +11% |
| Gross profit / gross margin | $448.8 / 73% | Margin: +1 percentage point | $1,229.7 / 71% | Margin: -1 percentage point |
| Operating income / operating margin | $128.5 / 21% | Income: +6% | $294.1 / 17% | Income: -16% |
| Net income | $135.2 | +25% | $378.3 | +26% |
| Diluted EPS | $0.83 | vs. $0.67 | $2.32 | vs. $1.84 |
| Operating cash flow | $82.6 | vs. $142.7 | $853.6 | vs. $717.1 |
- Subscription services gross margin was 85% in both comparison periods. Professional services gross margin was 23% for the quarter (up from 20%) and 18% for nine months (down from 20%).
- Other income, net was $42.2 million for the quarter and $111.3 million for nine months, substantially higher than the prior-year periods, primarily because of higher interest income. This helped lift net income despite weaker nine-month operating income.
- Research and development expense rose 24% for the quarter and 23% for nine months; total stock-based compensation was $101.2 million and $294.8 million, respectively.
Liquidity and cash flow
- At October 31, cash and cash equivalents were $743.7 million and short-term investments were $3.20 billion, totaling approximately $3.94 billion. Current assets were $4.34 billion and current liabilities $768.3 million.
- Total liabilities were $846.0 million, including lease liabilities; the filing reports no borrowings or other debt balance. Management said available cash, investments, and operating cash flows should cover working capital and capital expenditure needs for at least 12 months.
- Nine-month investing cash outflow was $989.6 million, primarily reflecting purchases of short-term investments net of maturities and sales. Financing cash outflow was $5.7 million.
Material changes, outlook, and notable items
- R&D Solutions drove most subscription growth: quarterly subscription revenue increased $41 million from R&D and $12 million from Commercial Solutions. For nine months, the respective increases were $77 million and $31 million. R&D Solutions represented approximately 47% of subscription revenue for the nine-month period.
- Since February 1, 2023, master agreements for multi-year orders generally give customers a termination-for-convenience right. Veeva says this changes revenue recognition and will reduce FY2024 revenue; the related contract asset from these orders was immaterial at October 31. Starting in FY2025, revenue recognized from such orders is generally expected to align with amounts invoiced for the relevant term.
- Management expects FY2024 total and subscription revenue growth rates to decline from FY2023, and operating margin to decrease, reflecting the contract change and planned investment in hiring, product development, and operating expenses. It expects revenue growth to accelerate in FY2025 versus FY2024, partly because of the lower FY2024 comparison base.
- Management expects professional services revenue to grow in FY2024’s final quarter, but says year-over-year growth will be pressured by increased project scrutiny and a more challenging macroeconomic environment. It also expects fourth-quarter operating cash flow to be substantially below the first nine months, and estimates the R&D capitalization requirements under the 2017 Tax Cuts and Jobs Act will reduce FY2024 operating cash flow by approximately $90 million.
- The nine-month effective tax rate was 6.7%, versus 20.0%, primarily reflecting $72 million of excess tax benefits from equity compensation, largely related to the CEO’s February 2023 option exercise. The quarterly effective tax rate was 20.8%, versus 19.0%.
- All outstanding Class B shares converted into Class A shares on October 15, 2023. The company also notes its planned migration of CRM applications from Salesforce to Veeva Vault: Vault CRM was sold to an early adopter, general availability was planned for April 2024, and existing CRM customers are required to migrate by September 1, 2030.
Risks and contingencies
- Veeva is engaged in multiple significant disputes, including IQVIA litigation and an appeal in the Medidata matter; Mednet litigation remains in discovery. The company says outcomes cannot be predicted and it cannot meaningfully estimate potential losses in these matters. It has not accrued a liability for certain IQVIA litigation fee arrangements.
- Key disclosed business risks include cybersecurity or service outages, intense competition, customer concentration, adoption of newer products, and execution of the CRM migration. The filing also highlights macroeconomic and life-sciences industry uncertainty, customer project scrutiny, foreign-exchange exposure, and evolving data privacy and regulatory requirements.
- The investment portfolio is exposed to interest-rate changes: the filing estimates an immediate 100-basis-point rate increase would reduce portfolio market value by $38 million. Management does not expect credit losses on available-for-sale investments to be material.
- Management stated disclosure controls were effective at a reasonable assurance level as of October 31, 2023, with no material changes to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Track subscription growth, renewal and expansion trends, and the revenue-recognition effect of termination-for-convenience rights, separately from billing metrics.
- Monitor operating margin and cash generation as expenses and stock-based compensation rise; distinguish recurring operating performance from interest income and equity-compensation tax benefits.
- Assess execution, customer retention, and potential disruption or competitive losses during the Salesforce-to-Vault CRM transition.
- Review the status and potential financial exposure of IQVIA, Medidata, and Mednet proceedings; the filing does not provide a clear estimate of possible losses.
- Check management’s FY2024 and FY2025 growth outlook against subsequent results, including the estimated $90 million FY2024 cash-flow impact of R&D tax amortization.